Newron Pharmaceuticals S.p.A.’s evenamide has shown signs of long-term safety and efficacy as an add-on therapy in a Phase II treatment-resistant schizophrenia (TRS) trial, sparking the advancement of pivotal development for the key value driver.
Evenamide blocks voltage-gated sodium channels (VGSCs), which is theorized to normalize glutamate release induced by aberrant sodium channel activity without...